These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 27086914)

  • 1. The oleocanthal-based homovanillyl sinapate as a novel c-Met inhibitor.
    Mohyeldin MM; Akl MR; Ebrahim HY; Dragoi AM; Dykes S; Cardelli JA; El Sayed KA
    Oncotarget; 2016 May; 7(22):32247-73. PubMed ID: 27086914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olive phenolics as c-Met inhibitors: (-)-Oleocanthal attenuates cell proliferation, invasiveness, and tumor growth in breast cancer models.
    Akl MR; Ayoub NM; Mohyeldin MM; Busnena BA; Foudah AI; Liu YY; Sayed KA
    PLoS One; 2014; 9(5):e97622. PubMed ID: 24849787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The indole alkaloid meleagrin, from the olive tree endophytic fungus Penicillium chrysogenum, as a novel lead for the control of c-Met-dependent breast cancer proliferation, migration and invasion.
    Mady MS; Mohyeldin MM; Ebrahim HY; Elsayed HE; Houssen WE; Haggag EG; Soliman RF; El Sayed KA
    Bioorg Med Chem; 2016 Jan; 24(2):113-22. PubMed ID: 26692349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (-)-Oleocanthal as a c-Met inhibitor for the control of metastatic breast and prostate cancers.
    Elnagar AY; Sylvester PW; El Sayed KA
    Planta Med; 2011 Jul; 77(10):1013-9. PubMed ID: 21328179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel c-Met inhibitory olive secoiridoid semisynthetic analogs for the control of invasive breast cancer.
    Mohyeldin MM; Busnena BA; Akl MR; Dragoi AM; Cardelli JA; El Sayed KA
    Eur J Med Chem; 2016 Aug; 118():299-315. PubMed ID: 27258622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ψ-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling.
    Ding J; Wen W; Xiang D; Yin P; Liu Y; Liu C; He G; Cheng Z; Yin J; Sheng C; Zhang W; Nan F; Ye W; Zhang X; Wang H
    Oncotarget; 2015 May; 6(13):11627-39. PubMed ID: 25890498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rutin as A Novel c-Met Inhibitory Lead for The Control of Triple Negative Breast Malignancies.
    Elsayed HE; Ebrahim HY; Mohyeldin MM; Siddique AB; Kamal AM; Haggag EG; El Sayed KA
    Nutr Cancer; 2017; 69(8):1256-1271. PubMed ID: 29083228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The HGF inhibitory peptide HGP-1 displays promising in vitro and in vivo efficacy for targeted cancer therapy.
    Chen L; Li C; Zhu Y
    Oncotarget; 2015 Oct; 6(30):30088-101. PubMed ID: 26254225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.
    Zhao Y; Zhang J; Tian Y; Xue C; Hu Z; Zhang L
    Drug Des Devel Ther; 2015; 9():4897-907. PubMed ID: 26345996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (1S,2E,4S,7E,11E)-2,7,11-Cembratriene-4,6-diol semisynthetic analogs as novel c-Met inhibitors for the control of c-Met-dependent breast malignancies.
    Ebrahim HY; Mohyeldin MM; Hailat MM; El Sayed KA
    Bioorg Med Chem; 2016 Nov; 24(22):5748-5761. PubMed ID: 27681240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
    Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
    Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 13
    Souid S; Elsayed HE; Ebrahim HY; Mohyeldin MM; Siddique AB; Karoui H; El Sayed KA; Essafi-Benkhadir K
    Mol Carcinog; 2018 Nov; 57(11):1507-1524. PubMed ID: 29978911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olive secoiridoids and semisynthetic bioisostere analogues for the control of metastatic breast cancer.
    Busnena BA; Foudah AI; Melancon T; El Sayed KA
    Bioorg Med Chem; 2013 Apr; 21(7):2117-27. PubMed ID: 23403296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
    Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
    Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Norstictic Acid Inhibits Breast Cancer Cell Proliferation, Migration, Invasion, and In Vivo Invasive Growth Through Targeting C-Met.
    Ebrahim HY; Elsayed HE; Mohyeldin MM; Akl MR; Bhattacharjee J; Egbert S; El Sayed KA
    Phytother Res; 2016 Apr; 30(4):557-66. PubMed ID: 26744260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro.
    Dai Y; Siemann DW
    Mol Cancer Ther; 2010 Jun; 9(6):1554-61. PubMed ID: 20515943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential Antitumor Activity of SIM-89 in Non-Small Cell Lung Cancer Cells.
    Pei J; Chu T; Shao M; Teng J; Sha H; Gu A; Li R; Qian J; Mao W; Li Y; Han B
    Yonsei Med J; 2017 May; 58(3):581-591. PubMed ID: 28332364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Boswellia frereana suppresses HGF-mediated breast cancer cell invasion and migration through inhibition of c-Met signalling.
    Parr C; Ali AY
    J Transl Med; 2018 Oct; 16(1):281. PubMed ID: 30314527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
    Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
    Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors.
    Bladt F; Faden B; Friese-Hamim M; Knuehl C; Wilm C; Fittschen C; Grädler U; Meyring M; Dorsch D; Jaehrling F; Pehl U; Stieber F; Schadt O; Blaukat A
    Clin Cancer Res; 2013 Jun; 19(11):2941-51. PubMed ID: 23553846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.